Aktis Oncology, Inc.
AKTSBiotechnology
$15.93−5.46%As of Oct 30vs prior close
- Market cap
- $856.2M
- P/E (TTM)
- –
- From 52W high
- −50.57%
- EPS (LTM)
- -$1.70
- Revenue (LTM)
- $10.1M
- Net margin
- -727.04%
Nomior Score
41
Steady ProfileBottom 31% of the scored universe
Growth49
Quality45
Value44
Momentum—
Resilience41
Growth
$10.1Mrevenue, LTM
YE22 $0LTM $10.1M
Connections
Revenue to profitYE25
The net loss was 981% of revenue, narrower by 1977 pts on a year.
Who owns it
2funds, 2 tracked portfolios